Ertugliflozin, the sodium-glucose cotransporter 2 (SGLT2) inhibitor class, now has shown evidence of renal benefits roughly on par with the other three drugs.
Treatment of patients with type 2 diabetes and established atherosclerotic cardiovascular disease (CVD) with ertugiflozin (Steglatro) led to significant reductions in the incidence of four prespecified, exploratory kidney endpoints in the VERTIS CV trial, which included more than 8200 patients.
Most notable of the new exploratory analyses is a composite of time to a sustained 40% reduction from baseline in estimated glomerular filtration rate (eGFR) or time to renal dialysis, transplant, or death, the incidence for which was a significant 34% lower with ertugliflozin treatment.
Source: Medscape